Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases: Results of a safety and feasibility study in the Netherlands Journal Article

   

Authors:	Buisman, F. E.; Grünhagen, D. J.; Homs, M. Y. V.; Grootscholten, C.; Filipe, W. F.; Kemeny, N. E.; Cercek, A.; D’Angelica, M. I.; Donswijk, M. L.; van Doorn, L.; Emmering, J.; Jarnagin, W. R.; Kingham, T. P.; Klompenhouwer, E. G.; Kok, N. F. M.; Kuiper, M. C.; Moelker, A.; Prevoo, W.; Versleijen, M. W. J.; Verhoef, C.; Kuhlmann, K. F. D.; Groot Koerkamp, B.
Article Title:	Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases: Results of a safety and feasibility study in the Netherlands
Abstract:	Background: The 10-year overall survival with adjuvant hepatic arterial infusion pump (HAIP) chemotherapy after resection of colorectal liver metastases (CRLMs) was 61% in clinical trials from Memorial Sloan Kettering Cancer Center. A pilot study was performed to evaluate the safety and feasibility of adjuvant HAIP chemotherapy in patients with resectable CRLMs. Study Design: A phase II study was performed in two centers in The Netherlands. Patients with resectable CRLM without extrahepatic disease were eligible. All patients underwent complete resection and/or ablation of CRLMs and pump implantation. Safety was determined by the 90-day HAIP-related postoperative complications from the day of pump placement (Clavien–Dindo classification, grade III or higher) and feasibility by the successful administration of the first cycle of HAIP chemotherapy. Results: A total of 20 patients, with a median age of 57 years (interquartile range [IQR] 51–64) were included. Grade III or higher HAIP-related postoperative complications were found in two patients (10%), both of whom had a reoperation (without laparotomy) to replace a pump with a slow flow rate or to reposition a flipped pump. No arterial bleeding, arterial dissection, arterial thrombosis, extrahepatic perfusion, pump pocket hematoma, or pump pocket infections were found within 90 days after surgery. After a median of 43 days (IQR 29–52) following surgery, all patients received the first dose of HAIP chemotherapy, which was completed uneventfully in all patients. Conclusion: Pump implantation is safe, and administration of HAIP chemotherapy is feasible, in patients with resectable CRLMs, after training of a dedicated multidisciplinary team. © 2019, The Author(s).
Journal Title:	Annals of Surgical Oncology
Volume:	26
Issue:	13
ISSN:	1068-9265
Publisher:	Springer
Date Published:	2019-12-01
Start Page:	4599
End Page:	4607
Language:	English
DOI:	10.1245/s10434-019-07973-w
PUBMED:	31641947
PROVIDER:	scopus
PMCID:	PMC6863781
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074197107&doi=10.1245%2fs10434-019-07973-w&partnerID=40&md5=bfde44bcc2bd1dec84892783494d3f32
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156796